wizard

[wizard @mrktwizard]

@cigs1234 I’m also thoughtful about Pfizer’s oral GLP-1 (danuglipron) which poses as an active competitor. If it shows equal or superior efficacy, it could take market share from $VKTX

[wizard @mrktwizard]

@cigs1234 Two questions.

Why do you thing a big pharma player hasn’t yet acquired them?

What specific advantages does VK2735 have over $LLY’s Mounjaro and $NVO’s Wegovy/Ozempic beyond simultaneous diabetes/obesity approval?